Hemostatic Markers in Congestive Heart Failure Dogs with Mitral Valve Disease

Table 2

Comparison of selected coagulation, hematology, and blood chemistry parameters among various NYHA functional classes of CHF group and control group.

	Control; ( = 50)	NYHA functional class				Total patients; ( = 58)
		I; ( = 2)	II; ( = 19)	III; ( = 32)	IV; ( = 5)
PT (sec.)	7.1 ± 0.5^1a	7.0 ± 0.1^abc	6.9 ± 0.3^ab	6.8 ± 0.3^bc	6.5 ± 0.3^c	6.9 ± 0.3^2
APTT (sec.)	12.2 ± 0.7^1a	12.3 ± 0.3^a	12.0 ± 0.4^a	12.0 ± 0.6^a	11.7 ± 0.4^a	12.0 ± 0.5^1
Fibrinogen (mg/dL)	175.2 ± 37.4^1a	223.5 ± 55.0^ab	268.8 ± 88.5^b	275.9 ± 99.5^b	351.8 ± 83.9^c	278.3 ± 94.9^2
D-dimer (g/mL)	117.2 ± 36.9^1a	197.0 ± 45.3^ab	419.2 ± 173.2^b	742.8 ± 300.6^c	1349.8 ± 445.4^d	670.3 ± 380.7^2
ATIII (%)	112.6 ± 16.5^1a	88.7 ± 4.5^abc	87.2 ± 21.0^b	84.7 ± 27.1^b	59.2 ± 23.1^c	83.5 ± 25.2^2
PC (%)	110.2 ± 12.9^1a	99.8 ± 8.3^ab	101.2 ± 24.6^ab	93.3 ± 33.3^b	57.3 ± 21.7^c	93.0 ± 31.1^2
F.VII (%)	99.9 ± 15.8^1a	101.0 ± 8.5^ab	124.6 ± 36.5^b	125.8 ± 23.5^b	132.9 ± 15.9^b	125.2 ± 27.7^2
F.VIII (%)	98.1 ± 12.9^1a	112.4 ± 10.5^ab	124.7 ± 29.0^b	124.0 ± 26.0^b	139.3 ± 10.2^b	125.1 ± 25.8^2
HCT (%)	37.4 ± 3.0^1a	42.5 ± 2.3^ab	42.4 ± 6.7^b	41.8 ± 7.0^b	41.0 ± 8.2^ab	42.0 ± 6.7^2
PLT (×10^3/L)	259.8 ± 45.5^1a	257.5 ± 109.6^ab	359.5 ± 122.8^b	355.5 ± 136.3^b	304.8 ± 104.7^ab	349.1 ± 128.0^2
TP (g/dL)	6.5 ± 0.5^1a	7.0 ± 0.3^ab	7.6 ± 1.0^b	7.5 ± 1.5^b	6.7 ± 1.1^ab	7.5 ± 1.3^2
ALB (g/dL)	3.1 ± 0.3^1a	3.4 ± 0.6^ab	3.5 ± 0.6^b	3.4 ± 0.5^b	2.9 ± 0.5^a	3.4 ± 0.6^2

Different superscript numbers indicate statistical significance between MVD group and control group at P < 0.05. ^a,b,c,dDifferent superscript letters indicate statistical significance among various NYHA classes of CHF group and control group at P < 0.05.